Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Effective treatment for pancreatic cancer remains challenging, particularly the treatment of pancreatic ductal adenocarcinoma (PDAC), which makes up more than 95% of all pancreatic cancers. Late diagnosis and failure of chemotherapy and radiotherapy are all too common, and many patients die soon after diagnosis. Here, we make the case for the increased use of molecular imaging in PDAC preclinical research and in patient management.

Original publication




Journal article


Eur J Nucl Med Mol Imaging

Publication Date





2442 - 2455


Molecular imaging, PET, Pancreatic ductal adenocarcinoma, Preclinical developments, SPECT, Animals, Humans, Molecular Imaging, Pancreas, Exocrine, Pancreatic Neoplasms, Translational Medical Research